Publicacións en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (48)

2025

  1. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score

    European heart journal, Vol. 46, Núm. 3, pp. 273-284

  2. Disrupted synaptic gene expression in Fabry disease: Findings from RNA sequencing

    Neurobiology of Disease, Vol. 209

2024

  1. Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers

    Translational Research, Vol. 269, pp. 47-63

  2. Colchicine in acutely decompensated heart failure: the COLICA trial

    European Heart Journal, Vol. 45, Núm. 45, pp. 4826-4836

  3. Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial

    Journal of the American Heart Association, Vol. 13, Núm. 19, pp. e035460

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  3. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  4. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

  3. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events among Patients with Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 6, pp. 552-560

  4. Ischemic etiology and prognosis in men and women with acute heart failure

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  5. Prognostic impact of hyponatraemia and hypernatraemia at admission and discharge in heart failure patients with preserved, mid-range and reduced ejection fraction

    Internal Medicine Journal, Vol. 51, Núm. 6, pp. 930-938

2020

  1. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction

    Internal Medicine Journal, Vol. 49, Núm. 12, pp. 1505-1513

  2. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

    Current Heart Failure Reports, Vol. 16, Núm. 6, pp. 304-314

2018

  1. Exercise-related severe cardiac events

    Scandinavian Journal of Medicine and Science in Sports, Vol. 28, Núm. 4, pp. 1404-1411